Impact of Endocrine Therapy on Osteoporosis Risk in Women with Breast Cancer Across Different Hormonal Stages: A Review DOI Creative Commons

Beatriz Gomes,

Nuno Vale

Current Oncology, Journal Year: 2025, Volume and Issue: 32(6), P. 305 - 305

Published: May 26, 2025

Breast cancer is the leading cause of death among women, and its treatment often involves chemotherapy hormone therapy, which can compromise bone mineral density (BMD). Tamoxifen, a selective estrogen receptor modulator, has different effects depending on patient’s hormonal status. On one hand, in postmenopausal it protective effect BMD; other premenopausal accelerate loss, increasing risk osteoporosis fractures. The reduction levels during key factor this loss. This review underscores importance early assessment regular monitoring density, along with adoption individualized pharmacological non-pharmacological strategies, such as calcium vitamin D supplementation physical exercise, to preserve health women breast undergoing endocrine therapy.

Language: Английский

Cross-Population Analysis of Breast CancerTranscriptomics: Comparative Insights Between Caucasian and Indian Patients DOI Creative Commons
Anuraj Nayarisseri, D. Ghosh, Srinivas Bandaru

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Abstract Ethnic diversity in breast cancer often results overlapping genetic profiles, complicating prognosis despite evolving classification methods. The present study examines transcriptomic variations between Caucasian and Indian populations through a cross-population analysis to assess whether genes differentially expressed among women show similar patterns women. Utilizing datasets from middle-aged with (SRA Project: SRP375823), we performed RNA-seq using the GATK Tuxedo II pipelines identify genes, followed by functional enrichment analysis. We identified eleven genes—mTOR, BARD1, RAD50, ADIPOQ, PMS2, ARID5B, NHERF1, SPEN, SDHB, MYH10, APC—that were significantly associated population. To impact of ethnic variability on gene expression, analyzed expression aforementioned patients. found that mTOR, BARD1, RAD50, ADIPOQ upregulated, PMS2was downregulated both populations, suggesting their universal role progression. However, ARID5B, SDHB, APC displayed population-specific differences, downregulation observed only patients no difference populations. These findings reveal differences highlighting need consider research treatment strategies.

Language: Английский

Citations

0
Genomic Landscape of Breast Cancer: Study Across Diverse Ethnic Groups DOI Creative Commons
Asbiel Felipe Garibaldi-Ríos, Luis E. Figuera, Guillermo Moisés Zúñiga‐González

et al.

Diseases, Journal Year: 2025, Volume and Issue: 13(3), P. 86 - 86

Published: March 17, 2025

Background: Breast cancer (BC) is the most common among women worldwide, with incidence and mortality rates varying across ethnic groups due to sociodemographic, clinicopathological, genomic differences. This study aimed characterize landscape of BC in diverse using computational tools explore these variations. Methodology: cBioPortal was used analyze genomic, sociodemographic data from 1084 samples. Mutated genes were classified based on GeneCards platform data. Enrichment analysis performed CancerHallmarks, not found compared MSigDB’s Hallmark Gene Sets. Genes absent both further analyzed NDEx through Cytoscape.org their role cancer. Results: Significant differences (p < 0.05) observed sex, tumor subtypes, genetic ancestry, median fraction altered genome, mutation count, frequencies groups. We identified frequently mutated genes. Some be associated classic hallmarks, such as replicative immortality, sustained proliferative signaling, evasion growth suppressors. However, exact some remains unclear, highlighting need for research better understand involvement biology. Conclusions: significant clinicopathological variations While key hallmarks found, incomplete characterization highlights research, especially focusing groups, biology improve personalized treatments.

Language: Английский

Citations

0
The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior DOI Creative Commons
Claudia Cifuentes,

Lydia Horndler,

P. Grosso

et al.

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: April 12, 2025

Recent research from our group has shown that the overexpression of wild-type RAS-family GTPase RRAS2 drives onset triple-negative breast cancer (TNBC) in mice following one or more pregnancies. This phenomenon mirrors human TNBC, where is overexpressed approximately 75% cases, particularly tumors associated with postpartum period. These findings underscore relevance R-RAS2 TNBC development and progression. We conducted RNA sequencing on derived conditional knock-in overexpressing to identify somatic mutation landscape these mice. Additionally, we developed a cell line RRAS2-overexpressing mice, enabling loss-of-function studies investigate role various pathobiological parameters cells, including migration, invasiveness, metabolic activity, metastatic spread. Furthermore, proteomic analysis freshly isolated tumor identified plasma membrane receptors interacting R-RAS2. Our demonstrate driven by exhibits pattern mutations similar those observed cancer, genes involved stemness, extracellular matrix interactions, actin cytoskeleton regulation. Proteomic revealed interacts 245 membrane-associated proteins, key solute carriers metabolism (CD98/LAT1, GLUT1, basigin), adhesion interaction proteins (CD44, EpCAM, MCAM, ICAM1, integrin-α6, integrin-β1), stem markers (β1-catenin, α1-catenin, PTK7, CD44). show regulates CD98/LAT1 transporter-mediated mTOR pathway activation mediates CD44-dependent migration invasion, thus providing mechanism which promotes metastasis. associates CD44, CD98/LAT1, other regulate reorganization, distant metastasis formation TNBC. establish as central driver malignancy highlight its potential promising therapeutic target, aggressive, postpartum-associated cancers.

Language: Английский

Citations

0
Impact of Endocrine Therapy on Osteoporosis Risk in Women with Breast Cancer Across Different Hormonal Stages: A Review DOI Creative Commons

Beatriz Gomes,

Nuno Vale

Current Oncology, Journal Year: 2025, Volume and Issue: 32(6), P. 305 - 305

Published: May 26, 2025

Breast cancer is the leading cause of death among women, and its treatment often involves chemotherapy hormone therapy, which can compromise bone mineral density (BMD). Tamoxifen, a selective estrogen receptor modulator, has different effects depending on patient’s hormonal status. On one hand, in postmenopausal it protective effect BMD; other premenopausal accelerate loss, increasing risk osteoporosis fractures. The reduction levels during key factor this loss. This review underscores importance early assessment regular monitoring density, along with adoption individualized pharmacological non-pharmacological strategies, such as calcium vitamin D supplementation physical exercise, to preserve health women breast undergoing endocrine therapy.

Language: Английский

Citations

0